Update shared on04 Sep 2025
Genmab’s consensus price target was unchanged at DKK1942, as strong sales momentum and positive pipeline updates were offset by concerns about rising competition and tempered long-term growth expectations.
Analyst Commentary
- Bullish analysts are raising price targets following stronger-than-expected sales momentum for Genmab's key oncology products.
- Positive clinical trial updates and pipeline progress are driving optimism on future revenue growth.
- Improved operational efficiencies and margin expansion are supporting upward revisions from some analysts.
- Bearish analysts cite increasing competitive pressures in the oncology segment, leading to more conservative growth projections.
- JPMorgan highlights tempered expectations for long-term top-line growth, resulting in a downward price target adjustment.
What's in the News
- Genmab reported positive Phase 3 results for epcoritamab (a bispecific antibody) plus rituximab and lenalidomide in relapsed/refractory follicular lymphoma, showing significant improvement in ORR and PFS; the FDA granted priority review and Breakthrough Therapy Designation for this combination.
- The company raised its 2025 revenue and operating profit guidance, with new ranges of $3,500–$3,700 million for revenue and $1,055–$1,405 million for operating profit.
- The FDA granted Breakthrough Therapy Designation to rinatabart sesutecan (Rina-S), an antibody-drug conjugate, for recurrent or progressive endometrial cancer, supporting ongoing late-stage trials in various solid tumors.
- Updated data from the Phase 2 EPCORE NHL-6 trial demonstrated outpatient feasibility and consistent safety profile for subcutaneous epcoritamab monotherapy in relapsed/refractory DLBCL.
- New results from the Phase 1b/2 EPCORE NHL-2 trial showed high response rates for epcoritamab combined with R-ICE chemotherapy in DLBCL eligible for stem cell transplant, though this combination is not yet approved.
Valuation Changes
Summary of Valuation Changes for Genmab
- The Consensus Analyst Price Target remained effectively unchanged, at DKK1942.
- The Future P/E for Genmab has significantly risen from 14.65x to 93.78x.
- The Consensus Revenue Growth forecasts for Genmab remained effectively unchanged, at 11.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.